BIO: New board of directors
The Biotechnology Innovation Organization (BIO) has elected its new Executive Committee directors for the 2022-2023 term: with the directors chosen during the 2022 BIO International Convention in San Diego in June.
“On behalf of our entire BIO organization, I want to congratulate our incoming Board directors and section leaders,” said Dr. Michelle McMurry-Heath, President & CEO of BIO. “This is a critical time for our industry. Our BIO Board – especially one as diverse and multi-faceted as this one – will help drive policies that keeps pace with innovation’s promise to cure disease, nourish society, and protect our planet.”
BIO’s Executive Committee directors for the 2022-2023 term are:
- Paul Hastings, Nkarta Therapeutics – Board Chair/Health Section Chair
- Elizabeth Lewis, Takeda Pharmaceuticals – Board Associate Vice Chair & Secretary
- Bradford Zakes, Ceravast Medical – BIO Board Treasurer
- Ted Love, Global Blood Therapeutics – Health Section Vice Chair
- Sylvia Wulf, AquaBounty Technologies – Agriculture & Environment Section Chair
- John Crowley, Amicus Therapeutics – Emerging Companies Section Chair
- Jeremy Levin, Ovid Therapeutics – Immediate Past Chair
- Erika Smith, ReNetX BIO – Emerging Companies Section Vice Chair
- Anna Rath, Vestaron
- Doug Doerfler, MaxCyte
- Stuart Arbuckle, Vertex Pharmaceuticals
- Christi Shaw, Kite, A Gilead Company
- Bill Sibold, Genzyme, A Sanofi Company
- Fritz Bittenbender, Genentech Roche
- Chris Boerner, Bristol Myers Squibb
- Eric Dube, Travere Therapeutics
- Sue Washer, Applied Genetic Technologies Corporation (AGTC)
- Aamir Malik, Pfizer
- Jannie Oosthuizen, Merck
- Victor Bulto, Novartis Pharmaceuticals
- Bill Newell, Sutro BioPharma
Additional directors who were confirmed as the Executive Advisory Board (EAB) to the Executive Committee:
- Ron Cohen, Acorda Therapeutics
- Rachel King, former BIO Board Chair
- John Maraganore, former BIO Board Chair
- Richard Pops, Alkermes
Newly Elected to the BIO Health Section Governing Board (2022-2025 Term):
- Jannie Oosthuizen, Merck
Newly Elected to the BIO Emerging Companies Section Governing Board (2022-2023 Term):
- Pablo Cagnoni, Rubius Therapeutics
- Kaye Foster, The Boston Consulting Group
- Mike Huckman, Real Chemistry
- Elizabeth Jeffords, Iolyx Therapeutics
- Sheila Mikhail, Asklepios BioPharmaceutical
Newly Elected to the BIO Agriculture and Environment Section Governing Board (2022-2024 Term):
- Angela Ailloni, Ginkgo Bioworks
- Rocco Morelli, Recombinetics
